# Sean P. Bohen

> Sean P. Bohen is President and CEO of Olema Oncology, a San Francisco clinical-stage biopharmaceutical company developing targeted therapies for women's cancers. An MD/PhD oncologist who spent 13 years at Genentech and four as AstraZeneca's Chief Medical Officer, he is now steering Olema's lead drug palazestrant - an oral complete estrogen receptor antagonist - through Phase 3 trials in ER+/HER2- metastatic breast cancer.

- **Role:** President and CEO at Olema Oncology
- **Organizations:** Olema Oncology, AltruBio (non-executive director), Gyroscope Therapeutics (former non-executive director), AstraZeneca (former), Genentech (former), Stanford University School of Medicine (former), National Cancer Institute (former)
- **Nationality:** American
- **Education:** B.S., Bacteriology, University of Wisconsin-Madison, M.D. and Ph.D., Biochemistry and Biophysics, University of California, San Francisco, Postdoctoral fellow, National Cancer Institute, Postdoctoral fellow; Clinical Instructor, Oncology, Stanford University School of Medicine / Howard Hughes Medical Institute
- **Known for:** Contributed to development of oncology drugs approved across HER2+ metastatic breast cancer, basal cell carcinoma, bladder cancer, chronic lymphocytic leukemia, mantle cell lymphoma, melanoma, non-small cell lung cancer, ovarian cancer and prostate cancer, Took Olema Oncology public on Nasdaq within two months of joining as CEO (November 2020), Led the clinical advancement of palazestrant (OP-1250) into Phase 3 trials for ER+/HER2- metastatic breast cancer

## Career timeline

- **pre-2002** — Postdoctoral fellowships at NCI and Stanford/HHMI; Adjunct Clinical Instructor in Oncology, Stanford
- **2002-2015** — 13 years at Genentech in roles up to Senior Vice President, Early Development (gRED)
- **2015-2019** — Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca
- **2020-09** — Named President and CEO of Olema Oncology; joined Board of Directors
- **2020-11** — Olema Oncology IPO on Nasdaq (OLMA)
- **2026** — Steering palazestrant through Phase 3 trials; advancing KAT6 inhibitor program

## Achievements

- Contributed to development of oncology drugs approved across HER2+ metastatic breast cancer, basal cell carcinoma, bladder cancer, chronic lymphocytic leukemia, mantle cell lymphoma, melanoma, non-small cell lung cancer, ovarian cancer and prostate cancer
- Took Olema Oncology public on Nasdaq within two months of joining as CEO (November 2020)
- Led the clinical advancement of palazestrant (OP-1250) into Phase 3 trials for ER+/HER2- metastatic breast cancer
- Earned both an M.D. and Ph.D. in biochemistry and biophysics from UCSF

## Latest updates

- **2026-03** — Spoke at industry conference touting palazestrant's 'superior exposure' versus rival oral SERDs.
- **2026-01** — Olema announced departure of its Chief Operating and Financial Officer.
- **2025-10** — CNBC reported analysts saw Olema shares with potential to more than double.

## Links

- Website: https://olema.com
- LinkedIn: https://www.linkedin.com/in/sean-bohen-md-phd-a625055/
- Twitter/X: https://twitter.com/OlemaOncology

---

Profile page: https://yespress.io/sean-bohen
Published by YesPress — https://yespress.io
Last updated: 2026-05-15